Evidence map›Paper›PMID 41612670›Full record

ArticleNeurodegenerative disease management2026

Real-world experience of ozanimod in adults with multiple sclerosis.

Jessica Cooperrider, Jeffrey Lambe, Michelle Chu, Mengke Du, Jennifer Reardon, Burhan Chaudry, Andrew Thorpe, Carrie M Hersh, Devon Conway

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurodegenerative disease management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jessica CooperriderCleveland Clinic, Neurology, Cleveland, OH, USA.
Jeffrey LambeCleveland Clinic, Mellen Center for Multiple Sclerosis, Cleveland, OH, USA.
Michelle ChuTouro University Nevada, Henderson, NV, USA.
Mengke DuCleveland Clinic, Mellen Center for Multiple Sclerosis, Cleveland, OH, USA.
Jennifer ReardonBristol Myers Squibb, US Medical Neuroscience, Princeton, NJ, USA.
Burhan ChaudryBristol Myers Squibb, US Medical Neuroscience, Princeton, NJ, USA.
Andrew ThorpeBristol Myers Squibb, US Medical Neuroscience, Princeton, NJ, USA.
Carrie M HershCleveland Clinic, Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.
Devon ConwayCleveland Clinic, Mellen Center for Multiple Sclerosis, Cleveland, OH, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimOzanimod is a second-generation sphingosine 1-phosphate receptor (S1PR) modulator approved for treatment of relapsing multiple sclerosis (MS). Data are lacking for ozanimod use in real-world clinical practice. This study aims to determine characteristics of people with MS (pwMS) prescribed ozanimod as well as ozanimod persistence, tolerability, safety, and effectiveness over one year.

methodsData were retrospectively collected for adults with MS or clinically isolated syndrome who received ozanimod at two tertiary MS centers.

resultsWe identified 206 pwMS for inclusion. Many (

conclusionOzanimod was well-tolerated with good treatment persistence, a favorable safety profile, and reductions in clinical and radiographic disease.

Indexed as

IndansMultiple SclerosisOxadiazolesSphingosine 1 Phosphate Receptor ModulatorsAdultFemaleHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeIndansOxadiazolesozanimodSphingosine 1 Phosphate Receptor Modulatorsdisease-modifying therapyeffectivenessMultiple sclerosisozanimodreal world evidence

Identifiers

PMID41612670
PMCPMC13390510

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.